share_log

Surgery Partners (NASDAQ:SGRY) Shareholder Returns Have Been Enviable, Earning 417% in 5 Years

Surgery Partners (NASDAQ:SGRY) Shareholder Returns Have Been Enviable, Earning 417% in 5 Years

手術合作伙伴(納斯達克: SGRY)股東的回報令人羨慕,在5年內賺取了417%。
Simply Wall St ·  08/28 18:18

We think all investors should try to buy and hold high quality multi-year winners. While the best companies are hard to find, but they can generate massive returns over long periods. For example, the Surgery Partners, Inc. (NASDAQ:SGRY) share price is up a whopping 417% in the last half decade, a handsome return for long term holders. This just goes to show the value creation that some businesses can achieve. Also pleasing for shareholders was the 21% gain in the last three months. The company reported its financial results recently; you can catch up on the latest numbers by reading our company report.

我們認爲所有投資者都應該嘗試購買並持有高質量多年贏家股票。雖然最好的公司很難找到,但它們能在長期內帶來巨大的回報。例如,納斯達克上的Surgery Partners公司(SGRY)股價在過去的半個多世紀漲幅高達417%,對於長揸者來說是一個可觀的回報。這正好說明了一些企業可以創造的價值。對股東來說,最近三個月裏股價上漲了21%,也是令人滿意的。公司最近公佈了財務業績,您可以通過閱讀我們的公司報告了解最新數據。

Since it's been a strong week for Surgery Partners shareholders, let's have a look at trend of the longer term fundamentals.

因爲Surgery Partners股東有一個強勁的一週,讓我們來看看更長期基本面的趨勢。

Because Surgery Partners made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings.

由於Surgery Partners在過去十二個月裏虧損,我們認爲市場目前可能更關注營業收入和營業收入增長。一般來說,預期沒有盈利的公司每年都應該增加營業收入,而且速度要快。一些公司願意推遲盈利來更快地增長營業收入,但在那種情況下,人們希望有良好的前線增長來彌補盈利的缺失。

In the last 5 years Surgery Partners saw its revenue grow at 11% per year. That's a pretty good long term growth rate. However, the share price gain of 39% during the period is considerably stronger. We usually like strong growth stocks but it does seem the market already appreciates this one quite well!

在過去的5年裏,Surgery Partners的營業收入年增長率爲11%。這是相當不錯的長期增長率。然而,在該期間,股價漲幅達39%,增長幅度明顯更大。我們通常喜歡增長強勁的股票,但似乎市場已經很好地讚賞了這家公司!

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

您可以看到以下收益和營收的變化情況(通過單擊圖像了解精確值)。

1724840333288
NasdaqGS:SGRY Earnings and Revenue Growth August 28th 2024
納斯達克上SGRY的盈利和營業收入增長情況於2024年8月28日發佈。

Surgery Partners is well known by investors, and plenty of clever analysts have tried to predict the future profit levels. You can see what analysts are predicting for Surgery Partners in this interactive graph of future profit estimates.

Surgery Partners爲投資者所熟知,許多聰明的分析師已嘗試預測未來的利潤水平。您可以在這個互動圖表中看到分析師對Surgery Partners的未來利潤預估。

A Different Perspective

不同的觀點

Surgery Partners shareholders are down 7.3% for the year, but the market itself is up 25%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Longer term investors wouldn't be so upset, since they would have made 39%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. It's always interesting to track share price performance over the longer term. But to understand Surgery Partners better, we need to consider many other factors. To that end, you should be aware of the 1 warning sign we've spotted with Surgery Partners .

Surgery Partners股東今年下跌了7.3%,但市場本身上漲了25%。即使是好股票的股價有時候也會下跌,但我們希望在對業務的基本指標看到改善之前不要太感興趣。長期投資者不會那麼沮喪,因爲他們在五年內每年可以賺取39%。如果基本數據繼續表明長期可持續增長,當前的拋售行爲可能值得考慮。長期跟蹤股價表現總是很有趣。但要更好地了解Surgery Partners,我們需要考慮許多其他因素。爲此,您應該注意我們發現的Surgery Partners的1個警示標誌。

We will like Surgery Partners better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying.

如果我們看到一些大額內部交易,我們會更喜歡Surgery Partners。在等待的時候,您可以查看這份免費的低估股票名單(主要是小市值股票),其中包括相當多的最近內部交易。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論